NovaBay Pharmaceuticals reports Q2 results
EMERYVILLE, Calif. A clinical stage biopharmaceutical company reported a 63.5% increase in license and collaboration revenue for second quarter.
License and collaboration revenue consists of the amortization of the upfront technology access fees previously paid by our corporate partners, and reimbursements for the funding of research and development activities, and payments for milestones achieved.
Meanwhile, second-quarter net loss totaled $0.3 million, or $0.01 per share, compared with a net loss of $2.4 million, or $0.11 per share, reported for second quarter 2008.
Research and development expenses for the quarter ended June 30 totaled $1.4 million, compared with $2.4 million for the year-ago period. The decrease was due to budget reductions at year end 2008 resulting in decreased headcount, and delayed research, development, and clinical expenses.
Investment group says Spartan’s board election process should change
GRAND RAPIDS, Mich. A supermarket operating company’s practice for electing members of its board of directors needs to change, an investment group said at the company’s annual meeting and in an accompanying letter.
CtW Investment Group called on the board of Spartan Stores to elect members of its board every year, while also expressing concern over auditor independence and executive pay, urging Spartan’s board to “declassify” the board in time for next year’s shareholder meeting.
“The annual election of directors is a predicate for accountability to Spartan shareholders,” CtW executive director Bill Patterson said at the company’s annual meeting.
Under its current election system, Spartan has a “classified” or “staggered” board, whereby board members are elected for different periods of time depending on their position.
“Classified boards such as Spartan’s are an outdated governance practice that serves to protect entrenched boards and prevent shareholders from holding accountable the directors charged with safe-guarding their investments in the company,” Patterson wrote.
Former Walmart executive named partner, chief merchandising officer at Blue Ocean Innovative Solutions
BENTONVILLE, Ark. Chuck Fehlig was named a partner and chief merchandising officer of Blue Ocean Innovative Solutions, the company announced earlier this month.
Fehlig comes to Blue Ocean by way of Walmart, where he was VP and divisional merchandise manager of OTC merchandise. In 2003, Fehlig was named VP/DMM of the year in Walmart and in 2009 he was honored with the “Outstanding Leadership Award” from the Wal-Mart Health and Wellness Division of Wal-Mart Stores.
Fehlig first joined Walmart as a staff pharmacist and has held several positions in pharmacy operations for the first 18 years of his 27-year career with the mass merchant, including director of professional affairs and divisional operations manager overseeing the operations of more than 850 pharmacies and 10,000 employees.
Fehlig holds a degree in pharmacy from the University of Arkansas for Medical Sciences.